CV 9201

Drug Profile

CV 9201

Alternative Names: CV-9201

Latest Information Update: 04 Oct 2015

Price : $50

At a glance

  • Originator CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 04 Oct 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer in Switzerland and Germany (Intradermal)
  • 07 Nov 2011 Immunogenicity & adverse events data from a phase I/IIa trial in Non-small cell lung cancer released by CureVac
  • 04 Mar 2011 CureVac completes enrolment in the phase II part of a phase I/II trial for Non-small cell lung cancer in Germany and Switzerland (NCT00923312)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top